Table 1. Clinical data from patients... | American Society of Hematology

Table 1.

Clinical data from patients with primary infection

Patient	Age, Sex	Days after infection, before HAART	Months after infection, after HAART	Treatment^*	CD4 T cells/μl, before HAART	CD4 T cells/μl, after HAART	Plasma HIV RNA (log copies/mL), before HAART	Plasma HIV RNA (log copies/mL), after HAART
1	43, Female	57	12	ZDV LAM SQV	453	789	4.7	2.7
2	28, Male	37	12	d4T LAM NFV	734	1085	4.7	1.0
3	24, Male	41	6	ZDV LAM NFV	740	742	5.3	2.1
4	31, Male	26	6	ZDV LAM NFV	451	361	6.3	3.6
5	34, Male	38	6	d4T ddI RTV HU	684	655	6.5	1.0
6	34, Male	35	6	ZDV LAM NFV	954	851	2.6	1.0
7	29, Male	32	12	ZDV LAM IDV^†	558	881	4.8	4.6
8	51, Male	33	6	ZDV LAM EFV	594	1079	5.3	1.0
9	32, Male	39	6	ZDV LAM RTV	371	1428	7.1	1.0
10	46, Male	31	6	LAM ABC RTV IDV	529	487	5.9	2.4
11	28, Male	31	6	ZDV ddI EFV	863	1496	4.3	1.8
12	34, Male	28	6	d4t ddI NFV RTV HU	194	353	6.9	1.9
13	34, Male	50	12	ZDV LAM RTV SQV	934	722	5.4	3.5
Mean ± SD	34 ± 8	37 ± 9			620 ± 230	840 ± 360	5.4 ± 1.2	2.1 ± 1.2

Patient	Age, Sex	Days after infection, before HAART	Months after infection, after HAART	Treatment^*	CD4 T cells/μl, before HAART	CD4 T cells/μl, after HAART	Plasma HIV RNA (log copies/mL), before HAART	Plasma HIV RNA (log copies/mL), after HAART
1	43, Female	57	12	ZDV LAM SQV	453	789	4.7	2.7
2	28, Male	37	12	d4T LAM NFV	734	1085	4.7	1.0
3	24, Male	41	6	ZDV LAM NFV	740	742	5.3	2.1
4	31, Male	26	6	ZDV LAM NFV	451	361	6.3	3.6
5	34, Male	38	6	d4T ddI RTV HU	684	655	6.5	1.0
6	34, Male	35	6	ZDV LAM NFV	954	851	2.6	1.0
7	29, Male	32	12	ZDV LAM IDV^†	558	881	4.8	4.6
8	51, Male	33	6	ZDV LAM EFV	594	1079	5.3	1.0
9	32, Male	39	6	ZDV LAM RTV	371	1428	7.1	1.0
10	46, Male	31	6	LAM ABC RTV IDV	529	487	5.9	2.4
11	28, Male	31	6	ZDV ddI EFV	863	1496	4.3	1.8
12	34, Male	28	6	d4t ddI NFV RTV HU	194	353	6.9	1.9
13	34, Male	50	12	ZDV LAM RTV SQV	934	722	5.4	3.5
Mean ± SD	34 ± 8	37 ± 9			620 ± 230	840 ± 360	5.4 ± 1.2	2.1 ± 1.2

Treatment abbreviations are as follows: ZDV indicates zidovudine; LAM, lamivudine; SQV, saquinavir; NFV, nelfinavir; RTV, ritonavir; HU, hydroxyurea; IDV, indinavir; EFV, efavirenz; ABC, abacavir.

†

Stopped after 3 months.

HAART indicates highly active antiretroviral therapy.

View Large

This Feature Is Available To Subscribers Only